Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 158 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. Clear all
Completed Phase 4 Interventional

Mild To Moderate Erectile Dysfunction Study

NCT00137072
View directory record Official record
Conditions
Impotence
Interventions
Viagra (Sildenafil Citrate) 100 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
33
States / cities
Birmingham, Alabama • Homewood, Alabama • Hoover, Alabama + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 3 Interventional

A Polysomnographic Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance

NCT00666770
View directory record Official record
Conditions
Transient Insomnia
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
5
States / cities
Glendale, California • San Diego, California • Overland Park, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Celecoxib Versus Naproxen in the 6-month Treatment of Knee Osteoarthritis

NCT00643799
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Celecoxib, Naproxen, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
51
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tempe, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics Of Celecoxib Test Formulations

NCT00925106
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Celebrex capsule, Test formulation D1, Test formulation D2, Test formulation D3
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Terminated Phase 3 Interventional Results available

Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder

NCT03768726
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Orange City, Florida • Fayetteville, Georgia • Smyrna, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain

NCT01701362
View directory record Official record
Conditions
Neuropathic Pain
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
105
States / cities
Huntsville, Alabama • Goodyear, Arizona • Phoenix, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population

NCT00150384
View directory record Official record
Conditions
Hypertension, Dyslipidemia
Interventions
Amlodipine/Atorvastatin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
106
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Assess The Pharmacokinetics, Safety, And Tolerability Of A Pregabalin Controlled Release Formulation Administered Following Various Sized Caloric Meals As Compared To The Pregabalin Immediate Release Formulation

NCT01080612
View directory record Official record
Conditions
Healthy
Interventions
330 mg pregabalin controlled release, 300 mg pregabalin immediate release
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines

NCT00232180
View directory record Official record
Conditions
Heart Failure
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
55 Years and older
Enrollment
2,743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
51
States / cities
Phoenix, Arizona • Loma Linda, California • Merced, California + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years

NCT01389596
View directory record Official record
Conditions
Epilepsy, Partial Seizures
Interventions
Pregabalin add-on therapy
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
4 Years to 16 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
20
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 4 Interventional Results available

GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)

NCT00373685
View directory record Official record
Conditions
Osteoarthritis
Interventions
Celecoxib, Any commercially available NSAID with the indication for osteoarthritis
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
55 Years to 99 Years
Enrollment
8,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
750
States / cities
Abbeville, Alabama • Alexander City, Alabama • Bay Minette, Alabama + 603 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed No phase listed Observational Results available

Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)

NCT01302080
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
sertraline, psychotherapy
Drug · Behavioral
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
44
States / cities
Dothan, Alabama • Imperial, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of 3 Sildenafil Oral Disintegrating Tablet Formulations Compared to the Standard Oral Tablet

NCT00950404
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Viagra 50 mg tablet, Formulation B ODT tablet 50 mg, Formulation C ODT tablet 50 mg, Formulation D ODT tablet 50 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 3 Interventional

A Trial to Assess Consumer Self-Selection and Use of Gabapentin for Occasional Sleeplessness in an Over-the-Counter Environment

NCT00659100
View directory record Official record
Conditions
Transient Insomnia
Interventions
Gabapentin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
35
States / cities
Anaheim, California • Bonita, California • Fallbrook, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients

NCT01271933
View directory record Official record
Conditions
Fibromyalgia
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
30
States / cities
Orange, California • Santa Ana, California • Ocala, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures

NCT00596466
View directory record Official record
Conditions
Epilepsy
Interventions
pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
34
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Fullerton, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)

NCT00280566
View directory record Official record
Conditions
Bipolar Mania, Bipolar Disorder
Interventions
Placebo, Ziprasidone Oral Capsule
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
73
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 3 Interventional

A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension

NCT00644605
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
sildenafil, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
24
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects Of Eplerenone On Serum Aldesterone And Plasma Renin Activity

NCT00990223
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Eplerenone or Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Miami, Florida • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 4 Interventional

Caduet in an Untreated Subject Population

NCT00332761
View directory record Official record
Conditions
Hypertension, Dyslipidemia
Interventions
Caduet
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
34
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 3 Interventional

A Safety Study Of Pregabalin In Fibromyalgia

NCT00282997
View directory record Official record
Conditions
Fibromyalgia
Interventions
pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
72
States / cities
Little Rock, Arkansas • Fresno, California • La Jolla, California + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Terminated No phase listed Observational Results available

Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis

NCT00688545
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid
Interventions
Celecoxib, nsNSAIDs
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
27
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Washington D.C., District of Columbia + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 2 Interventional

An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder

NCT00746967
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological, Sexual Arousal Disorder
Interventions
sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
82
States / cities
Huntsville, Alabama • Anchorage, Alaska • Tucson, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 12, 2026, 4:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects

NCT00866463
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 12, 2026, 4:07 PM EDT